Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Randomized, Placebo-Controlled, Double-Blind, Multi-Center Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects With Moderately Active Ulcerative Colitis

NCT00729872 is registered in ClinicalTrials.gov with ActoGeniX N.V. as lead sponsor.

NCT NCT00729872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00729872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Randomized, Placebo-Controlled, Double-Blind, Multi-Center Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects With Moderately Active Ulcerative Colitis
Lead sponsor
ActoGeniX N.V.
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2008
Completion date
September 30, 2009
Enrollment
60 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

moderately active ulcerative colitis